MX2015005601A - Dispersiones solidas de farmaco insoluble y metodo de preparacion de las mismas. - Google Patents

Dispersiones solidas de farmaco insoluble y metodo de preparacion de las mismas.

Info

Publication number
MX2015005601A
MX2015005601A MX2015005601A MX2015005601A MX2015005601A MX 2015005601 A MX2015005601 A MX 2015005601A MX 2015005601 A MX2015005601 A MX 2015005601A MX 2015005601 A MX2015005601 A MX 2015005601A MX 2015005601 A MX2015005601 A MX 2015005601A
Authority
MX
Mexico
Prior art keywords
active ingredient
insoluble drug
preparation
solid dispersion
solid dispersions
Prior art date
Application number
MX2015005601A
Other languages
English (en)
Other versions
MX367644B (es
Inventor
Augustin Pegan
Myoung Ki Baek
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2015005601A publication Critical patent/MX2015005601A/es
Publication of MX367644B publication Critical patent/MX367644B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/60—Mixing solids with solids
    • B01F23/66—Mixing solids with solids by evaporating or liquefying at least one of the components; using a fluid which is evaporated after mixing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/80—After-treatment of the mixture
    • B01F23/81—Grinding the mixture
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90—Heating or cooling systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90—Heating or cooling systems
    • B01F2035/99—Heating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
    • B01F27/40—Mixers with rotor-rotor system, e.g. with intermeshing teeth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una dispersión sólida caracterizada en que comprende éster 3-(4-benciloxi- fenil)-isoxazol-5-ilmetílico de ácido carbámico como un ingrediente activo y un polímero soluble en agua que tiene una temperatura de transición vítrea menor que el punto de fusión del ingrediente activo como un portador, y se prepara por la vía de la extrusión en estado fundido. La dispersión sólida de la presente invención notablemente incrementa la solubilidad y velocidad de disolución del ingrediente activo, que es un fármaco insoluble, para mejorar eficientemente la biodisponibilidad cuando se administra oralmente.
MX2015005601A 2012-11-07 2013-11-07 Dispersiones sólidas de fármaco insoluble y método de preparación de las mismas. MX367644B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120125516 2012-11-07
PCT/KR2013/010088 WO2014073889A1 (en) 2012-11-07 2013-11-07 Solid dispersions of insoluble drug and preparation method thereof

Publications (2)

Publication Number Publication Date
MX2015005601A true MX2015005601A (es) 2016-03-03
MX367644B MX367644B (es) 2019-08-29

Family

ID=50684915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005601A MX367644B (es) 2012-11-07 2013-11-07 Dispersiones sólidas de fármaco insoluble y método de preparación de las mismas.

Country Status (15)

Country Link
US (3) US9439970B2 (es)
EP (1) EP2917188B8 (es)
JP (1) JP6266006B2 (es)
KR (1) KR102191562B1 (es)
CN (1) CN105026378B (es)
AU (1) AU2013341930B2 (es)
BR (1) BR112015010243A2 (es)
CA (1) CA2890470C (es)
ES (1) ES2691305T3 (es)
HK (1) HK1216752A1 (es)
MX (1) MX367644B (es)
PL (1) PL2917188T3 (es)
RU (1) RU2646491C2 (es)
TR (1) TR201815394T4 (es)
WO (1) WO2014073889A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722568B1 (ko) * 2014-12-12 2017-04-03 강원대학교산학협력단 생약재 및 가용화제를 포함하는 고체분산체 및 그 제조방법
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
RU2743927C1 (ru) * 2020-07-10 2021-03-01 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Твердая дисперсия 4-(3-этокси-4-гидроксибензил)-5-оксо-5,6-дигидро-4H-[1,3,4]-тиадиазин-2-(2,4-дифторфенил)-карбоксамида для изготовления лекарственной формы и способ лечения хронических инфекционных заболеваний
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0580860T4 (da) * 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
WO2003077827A1 (fr) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
KR101002656B1 (ko) 2008-08-05 2010-12-22 대한민국 포도 비파괴 당도 선별장치
KR101157134B1 (ko) 2008-10-14 2012-06-22 이희영 다혈소판 혈장의 분리방법
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof

Also Published As

Publication number Publication date
US20160346258A1 (en) 2016-12-01
US9439970B2 (en) 2016-09-13
EP2917188B1 (en) 2018-08-01
EP2917188A4 (en) 2016-07-06
US20150283243A1 (en) 2015-10-08
EP2917188B8 (en) 2018-10-17
CN105026378B (zh) 2018-03-13
JP6266006B2 (ja) 2018-01-24
US9566268B2 (en) 2017-02-14
RU2015119243A (ru) 2016-12-27
HK1216752A1 (zh) 2016-12-02
US9724335B2 (en) 2017-08-08
BR112015010243A2 (pt) 2017-07-11
US20170105973A1 (en) 2017-04-20
ES2691305T3 (es) 2018-11-26
JP2015536978A (ja) 2015-12-24
CA2890470A1 (en) 2014-05-15
TR201815394T4 (tr) 2018-11-21
EP2917188A1 (en) 2015-09-16
AU2013341930A1 (en) 2015-05-21
WO2014073889A1 (en) 2014-05-15
MX367644B (es) 2019-08-29
CA2890470C (en) 2020-09-15
KR20140059146A (ko) 2014-05-15
AU2013341930B2 (en) 2017-05-04
KR102191562B1 (ko) 2020-12-15
PL2917188T3 (pl) 2019-04-30
CN105026378A (zh) 2015-11-04
RU2646491C2 (ru) 2018-03-05

Similar Documents

Publication Publication Date Title
AU2016219654A1 (en) Crystallization method and bioavailability
AU2016219653A1 (en) Crystallization Method and Bioavailability
MX2011011374A (es) Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.
MX2017008939A (es) Forma de dosificacion que incluye una solucion solida de drogas amorfas.
MX2015005601A (es) Dispersiones solidas de farmaco insoluble y metodo de preparacion de las mismas.
NZ748572A (en) Pharmaceutical compositions having improved storage stability
WO2014100418A3 (en) Orally disintegrating tablet formulation for enhanced bioavailability
NZ743320A (en) Method for preparing polymeric micelle containing anionic drug
SG194175A1 (en) Polymer conjugated prostaglandin analogues
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
WO2014207664A3 (en) Stable pharmaceutical composition of asenapine
PH12015502556A1 (en) Modified release formulation
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
NZ727834A (en) Fast acting orally disintegrating film
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
WO2012092486A3 (en) Modified release benzimidazole formulations
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
WO2013018050A3 (en) Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
CA2863371A1 (en) Pregabalin gr tablets
WO2016126058A3 (ko) 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
BR112017019364A2 (pt) dispersões sólidas
WO2016148455A3 (ko) 몬테루카스트의 생체이용률을 개선시키기 위한 방법
WO2014045307A3 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FG Grant or registration